Acorda Down Over 10% Ahead of FDA (ACOR)

Posted in pre-market 
October 9th, 2009

Acorda Therapeutics, Inc. (NASDAQ: ACOR) is getting hit hard this morning ahead of an expected FDA decision to make public the background material over Acorda’s Fampridine on or before October 12.  Shares are dowhn 11% at $19.86 on about 400,000 shares as of 8:20 AM EST.  Average volume is 450,000 shares and the 52-week trading range is $14.42 to $29.27.

UPDATE after 8:30 AM EST… FDA DATA:

http://www.fda.gov/AdvisoryCommittees/WhatsNew/default.htm

-JON OGG

Comments are closed

-->